ASCO 2019
ASCO 2019 Videos
Elderly Patients With Breast Cancer and CVD Risk Factors Found More Likely to Visit ER
Neratinib Improved PFS Compared With Lapatinib
EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy
Pazopanib Found Not Beneficial Following Metastasectomy
Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases
Neoadjuvant Therapy Tied to High Pathological Response Rates
Heparin Derivative CX-01 May Boost Standard AML Induction
Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit
Promising Early Results for Preoperative Atezolizumab
ASCT Reduced the Risk of Early Relapse for Some Patients
BRAF and MEK Inhibitors Deemed Superior to Anti–PD-1
Novel Metric Sheds Light on When Adverse Events May Occur
Results of Enfortumab Vedotin Monotherapy for Urothelial Cancer
Randomized Phase III Trial of Lenalidomide vs. Observation Alone
Association of PBAF Complex Mutations With Survival
Gilteritinib Superior to Salvage Chemo
Adjuvant Ipilimumab Determined to Increase Overall Survival
Update at 9 Years of the GETUG-AFU 16 Phase III Randomized Trial
Pembrolizumab Improves Survival in NSCLC
ASCO 2019 Complete Coverage
Talazoparib in Advanced HER2-Negative Breast Cancer and Other Solid Tumors Lacking BRCA1/2 Mutations
Researchers determined that gPALB2 may be a promising biomarker for talazoparib response.
Elderly Patients With Breast Cancer and CVD Risk Factors Found More Likely to Visit ER
Patients with diabetes, hypercholesterolemia, or CAD had 23.9%, 11.4%, and 19.2% increased costs, respectively, versus those without risk factors for CVD.
Can BRCA-Positive Patients With Breast Cancer Safely Become Pregnant?
The authors found that BRCA1-positive patients who became pregnant had improved disease-free survival, although there was no improvement in overall survival.
OS Benefit of Adding Atezolizumab to Nab-Paclitaxel for Patients With Advanced, PD-L1–Positive Triple-Negative Breast Cancer
Rates of 2-year OS were 51% and 37% in the subgroup of patients with detectable tumor levels of PD-L1 who received atezolizumab and placebo, respectively.
Neratinib Improved PFS Compared With Lapatinib in Pretreated HER2-Positive Metastatic Breast Cancer
Rates of grade 3 diarrhea were 2-fold higher for patient receiving neratinib vs lapatinib, although fewer patients discontinued neratinib due to a treatment-related AE.
Improved PFS for Pyrotinib Plus Capecitabine vs Placebo Plus Capecitabine in Trastuzumab-Pretreated Metastatic HER2-Positive Breast Cancer
Antitumor activity was also observed in the subgroup of patients receiving pyrotinib monotherapy following disease progression on placebo plus capecitabine.
OS Improvement With Addition of CDK4/6 Inhibitor to Endocrine Therapy in Younger Women With Metastatic Breast Cancer
This is the first study to demonstrate a statistically significant improvement in OS with the addition of a CDK4/6 inhibitor to endocrine therapy.
HER2 Intratumor Heterogeneity as a Biomarker of Nonresponse to Neoadjuvant Dual HER2-Targeted Therapy in HER2-Positive Breast Cancer
Evidence of HER2 intratumor heterogeneity was found in 10% of the patients enrolled in this study.
Efficacy of Maintenance Therapy After Induction Therapy in Patients With Nonsquamous NSCLC and Wild-Type EGFR
In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”
EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy Versus Gefitinib Alone
Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.
RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC
RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Early MRD Status After CAR-T Administration Predicted PFS, OS
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
Adding Apalutamide to ADT Prolongs Survival in mCSPC
In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.
Earlier Pembrolizumab Use May Be Beneficial in mUC
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
PET/CT Imaging for Recurrent PCa Detection More Accurate With PSMA
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
More Advanced PCa Diagnoses Followed USPSTF Screening Recommendations
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
Nonrelapse Mortality After CAR-T Therapy Remains High
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Margetuximab Improved PFS Compared With Trastuzumab in Pretreated Metastatic HER2-Positive Breast Cancer
The Fc fragment of therapeutic antibodies is believed to recognize specific receptors on immune cells and mediate immune functions through this interaction.
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2019
